ORNL’s Fulvia Pilat and Karren More recently participated in the inaugural 2023 Nanotechnology Infrastructure Leaders Summit and Workshop at the White House.
The Department of Energy’s Office of Science has selected three ORNL research teams to receive funding through DOE’s new Biopreparedness Research Virtual Environment initiative.
How did we get from stardust to where we are today? That’s the question NASA scientist Andrew Needham has pondered his entire career.
A team of scientists led by the Department of Energy’s Oak Ridge National Laboratory designed a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to develop new treatments for COVID-19 and other viral diseases.
Paul Langan will join ORNL in the spring as associate laboratory director for the Biological and Environmental Systems Science Directorate.
ORNL researchers used the nation’s fastest supercomputer to map the molecular vibrations of an important but little-studied uranium compound produced during the nuclear fuel cycle for results that could lead to a cleaner, safer world.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
Scientists at ORNL and the University of Tennessee, Knoxville, have found a way to simultaneously increase the strength and ductility of an alloy by introducing tiny precipitates into its matrix and tuning their size and spacing.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.